286 related articles for article (PubMed ID: 34286886)
21. Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients.
Calcaterra SL; Dafoe A; Tietbohl C; Thurman L; Bredenberg E
J Hosp Med; 2024 Jun; 19(6):460-467. PubMed ID: 38507276
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of an implementation of methadone maintenance treatment in China.
Marienfeld C; Liu P; Wang X; Schottenfeld R; Zhou W; Chawarski MC
Drug Alcohol Depend; 2015 Dec; 157():60-7. PubMed ID: 26601934
[TBL] [Abstract][Full Text] [Related]
23. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.
Dunn KE; Brooner RK; Stoller KB
J Subst Abuse Treat; 2021 Feb; 121():108197. PubMed ID: 33357606
[TBL] [Abstract][Full Text] [Related]
24. Changes In County-Level Access To Medications For Opioid Use Disorder After Medicare Coverage Of Methadone Treatment Began.
Harris SJ; Yarbrough CR; Abraham AJ
Health Aff (Millwood); 2023 Jul; 42(7):991-996. PubMed ID: 37406230
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Belcher AM; Cole TO; Massey E; Billing AS; Wagner M; Wooten W; Epstein DH; Hoag SW; Wickwire EM; Greenblatt AD; Colloca L; Rotrosen J; Magder L; Weintraub E; Wish ED; Kaptchuk TJ
JAMA Netw Open; 2023 Apr; 6(4):e237099. PubMed ID: 37043203
[TBL] [Abstract][Full Text] [Related]
26. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule.
Laks J; Kehoe J; Farrell NM; Komaromy M; Kolodziej J; Walley AY; Taylor JL
Addict Sci Clin Pract; 2021 Dec; 16(1):73. PubMed ID: 34961554
[TBL] [Abstract][Full Text] [Related]
27. Loneliness and Illicit Opioid Use Among Methadone Maintenance Treatment Patients.
Polenick CA; Cotton BP; Bryson WC; Birditt KS
Subst Use Misuse; 2019; 54(13):2089-2098. PubMed ID: 31232142
[No Abstract] [Full Text] [Related]
28. A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, health, and well-being.
Cooperman NA; Hanley AW; Kline A; Garland EL
J Subst Abuse Treat; 2021 Aug; 127():108468. PubMed ID: 34134880
[TBL] [Abstract][Full Text] [Related]
29. Gender-specific predictors of methadone treatment outcomes among African Americans at an urban clinic.
Lister JJ; Brown S; Greenwald MK; Ledgerwood DM
Subst Abus; 2019; 40(2):185-193. PubMed ID: 30888262
[No Abstract] [Full Text] [Related]
30. "
Checkley L; Steiger S; Knight KR
Subst Abus; 2022; 43(1):767-773. PubMed ID: 35112998
[No Abstract] [Full Text] [Related]
31. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
[TBL] [Abstract][Full Text] [Related]
32. Experience of patients on methadone maintenance treatment receiving take-home methadone doses during COVID-19 pandemic: A multi-site study from India.
Kathiresan P; Patel V; Jangra J; Chattopadhyay A; Abdus S; Jadhav M; Rao R; Arya A; Bansal PD; Chinggouman C; Bhad R; Ambekar A; Agrawal A; Chatterjee B; Yadav D
Asian J Psychiatr; 2024 May; 95():103979. PubMed ID: 38442535
[TBL] [Abstract][Full Text] [Related]
33. Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment.
Belcher AM; Cole TO; Greenblatt AD; Hoag SW; Epstein DH; Wagner M; Billing AS; Massey E; Hamilton KR; Kozak ZK; Welsh CJ; Weintraub E; Wickwire EM; Wish ED; Kaptchuk TJ; Colloca L
BMJ Open; 2019 Jun; 9(6):e026604. PubMed ID: 31230007
[TBL] [Abstract][Full Text] [Related]
34. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
35. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
[TBL] [Abstract][Full Text] [Related]
36. Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids.
Panwala V; Thorn E; Amiri S; Socias ME; Lutz R; Amram O
Am J Drug Alcohol Abuse; 2023 Sep; 49(5):597-605. PubMed ID: 37433122
[No Abstract] [Full Text] [Related]
37. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
[TBL] [Abstract][Full Text] [Related]
38. Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey.
Brothers S; Palayew A; Simon C; Coulter A; Strichartz K; Voyles N; Vincent L
Harm Reduct J; 2023 Mar; 20(1):31. PubMed ID: 36894968
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome.
Strang J; Marsden J; Cummins M; Farrell M; Finch E; Gossop M; Stewart D; Welch S
Addiction; 2000 Nov; 95(11):1631-45. PubMed ID: 11219367
[TBL] [Abstract][Full Text] [Related]
40. Mobile telephone delivered contingency management for encouraging adherence to supervised methadone consumption: feasibility study for an RCT of clinical and cost-effectiveness (TIES).
Metrebian N; Carr E; Goldsmith K; Weaver T; Pilling S; Shearer J; Woolston-Thomas K; Tas B; Cooper C; Getty CA; van der Waal R; Kelleher M; Finch E; Bijral P; Taylor D; Scott J; Strang J
Pilot Feasibility Stud; 2021 Jan; 7(1):14. PubMed ID: 33407950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
